Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

General Surgical Innovations aims to expand minimally invasive surgery (MIS)

This article was originally published in Clinica

Executive Summary

General Surgical Innovations (GSI) aims to raise $27 million from the sale of 2.5 million shares at an assumed price of $12. The amount could rise to $31 million if the underwriters' overallotment is exercised in full. The developer of balloon dissection systems for minimally invasive surgery plans to use $9 million of the proceeds of its IPO to expand sales of its Spacemaker systems. Part of the IPO proceeds will go towards expanding GSI's facility in Palo Alto, California.

You may also be interested in...



French OTC Industry Frustrated By Regulatory Clampdown in 2019

Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.

Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?

Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed is there a risk of delays to these products being able to demonstrate compliance?

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

Topics

UsernamePublicRestriction

Register

MT088058

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel